Clinical Trial Success and Data Outcomes: The success of Capricor's lead product candidate, CAP-1002, particularly in the ongoing HOPE-3 pivotal trial for Duchenne Muscular Dystrophy (DMD), is critical, and failure to meet primary endpoints or demonstrate sufficient efficacy could severely impact the company's prospects.

Regulatory Approval Process: Even if clinical trials are successful, Capricor must obtain regulatory approvals from agencies like the FDA and EMA for its product candidates, and there is no guarantee these approvals will be granted in a timely manner or at all.

Capital Requirements and Funding: Capricor is a development-stage company that has incurred and expects to continue to incur significant losses, requiring substantial additional capital to fund its operations, clinical trials, and potential commercialization efforts, which may not be available on favorable terms or at all.